Immunoglobulin (Ig) therapy is an expensive therapy. Unfortunately some insurance companies deny Ig therapy for primary immunodeficiency, until the insurer understands the rationale behind this expensive life sustaining therapy. They are very reluctant to approve expensive payments per year where indications are not substantiated.
The IDF Medical Advisory Committee issued a resolution in January 2016 regarding the danger posed by the arbitrary insurer requirement for a diagnostic vaccine challenge for all previously diagnosed individuals with Common Variable Immune Deficiency (CVID). Click here to read the resolution.
Below are some “how to” tips from a clinical immunologist that has been successful in overturning Ig denials, followed by some additional helpful information, including a link to sample appeal letters that should be tailored to the patient’s clinical history:
For additional information:
The AAAAI IVIG toolkit includes:
The AAAAI IVIG Toolkit has been approved by the AAAAI Board of Directors, and endorsed by the Clinical Immunology Society (CIS) and the Immune Deficiency Foundation (IDF).